The UK has approved on Thursday the use of GlaxoSmithKline drug to treat people at high risk of developing severe COVID-19 symptoms.
UK scientists said that the drug appears to be effective against the new Omicron variant.
The antibody treatment, sotrovimab, “is safe and effective at reducing the risk of hospitalisation and death in people with mild to moderate COVID-19 infection who are at an increased risk of developing severe disease”, the Medicines and Healthcare products Regulatory Agency (MHRA) said in a statement on Thursday.
Last month, the UK became the first country to approve molnupiravir, a potentially game-changing COVID-19 antiviral pill jointly developed by Merck and Ridgeback Biotherapeutics.
Britain faces the prospect of thousands of annual Covid deaths for years to come, scientists have warned.
Scientists said that the UK might learn to live with thousands of Covid-related deaths for years to come.
The Covid-19 vaccines don’t seem to be a long term solution for the health crisis as new variants emerge. People will have to live with it.
Seasonal waves of the virus will sweep the country every winter. It will join other seasonal viruses, including influenza. However, it will kill those with underlying conditions with the provided vaccines.
The numbers of Covid cases seem to establish through this summer, but it will rise again. A fourth wave is to occur this autumn. This is expected to occur yearly for a while.